{"id":17364,"date":"2026-05-29T03:38:23","date_gmt":"2026-05-29T03:38:23","guid":{"rendered":"https:\/\/nexplasmagen.com\/?p=17364"},"modified":"2026-05-29T03:38:23","modified_gmt":"2026-05-29T03:38:23","slug":"nexplasmagen-gagne-le-meilleur-pitch-medtech-au-tiequest-summit","status":"publish","type":"post","link":"https:\/\/nexplasmagen.com\/fr\/nexplasmagen-gagne-le-meilleur-pitch-medtech-au-tiequest-summit\/","title":{"rendered":"NexPlasmaGen gagne le meilleur pitch MedTech au TiEQuest Summit"},"content":{"rendered":"

Montr\u00e9al \/ 28 mai 2026 \u2013NexPlasmaGen vient de remporter la comp\u00e9tition de la cat\u00e9gorie MedTech du \ud835\udde7\ud835\uddf6\ud835\uddd8\ud835\udde4\ud835\ude02\ud835\uddf2\ud835\ude00\ud835\ude01 \ud835\udfee\ud835\udfec\ud835\udfee\ud835\udff2, avec une bourse de 15 000 CAD\u00a0!<\/h2>\n

 <\/p>\n

\ud83c\udf1f \ud835\uddda\ud835\uddee\ud835\uddf4\ud835\uddfb\ud835\uddee\ud835\uddfb\ud835\ude01\ud835\uddf2 \ud835\uddf1\ud835\uddf2 \ud835\uddf9\ud835\uddee \ud835\uddf0\ud835\uddee\ud835\ude01\ud835\uddf2\u0301\ud835\uddf4\ud835\uddfc\ud835\uddff\ud835\uddf6\ud835\uddf2 \ud835\udde0\ud835\uddf2\ud835\uddf1\ud835\udde7\ud835\uddf2\ud835\uddf0\ud835\uddf5Dr. Val\u00e9rie L\u00e9veill\u00e9<\/strong><\/a> \u2014 fondatrice et PDG de NexPlasmaGen Leveille<\/strong><\/a>
\nNexPlasmaGen fait progresser l\u2019innovation de rupture en oncologie gr\u00e2ce \u00e0 la technologie du plasma froid, en apportant l\u2019espoir de meilleurs r\u00e9sultats pour les patientes et patients et en red\u00e9finissant l\u2019avenir des traitements de pr\u00e9cision. \ud83e\ude7a\ud83d\udd2c\u2728<\/p>\n

NexPlasmaGen exprime sa profonde gratitude aux \ud835\uddfa\ud835\uddf2\ud835\uddfa\ud835\uddef\ud835\uddff\ud835\uddf2\ud835\ude00 \ud835\uddf1\ud835\ude02 \ud835\uddf7\ud835\ude02\ud835\uddff\ud835\ude06 \ud835\udde0\ud835\uddf2\ud835\uddf1\ud835\udde7\ud835\uddf2\ud835\uddf0\ud835\uddf5 pour leur temps, leur expertise et la qualit\u00e9 de leurs d\u00e9lib\u00e9rations\u00a0:
\n\u2022 Ken Spears<\/strong><\/a>, Boston Scientific
\n\u2022 Shiraz Patel<\/strong><\/a>, Halo Health
\n\u2022 Alex Norman<\/strong><\/a>, N49P
\n\u2022 Peyvand Melati<\/strong><\/a>, Axion Fund
\n\u2022 Andrew Opala<\/strong><\/a>, Preference Capital
\nVos perspectives et votre engagement continuent d\u2019\u00e9lever l\u2019\u00e9cosyst\u00e8me entrepreneurial.<\/p>\n

Un immense merci aux commanditaires de l\u2019\u00e9v\u00e9nement pour leur temps pr\u00e9cieux et leur contribution :
\nBaylis Medical Technologies<\/strong><\/a>, Kris Shah<\/strong><\/a>, Frank Baylis<\/strong><\/a>, ICICI Bank Canada<\/strong><\/a>, Himadar Maddipatla<\/strong><\/a>, Niloy Nath<\/strong><\/a>, Brampton Innovation District<\/strong><\/a>, Denise McClure<\/strong><\/a>, Tara Hunter<\/strong><\/a>, Suvid Ajmera<\/strong><\/a>, City of Toronto<\/strong><\/a>, Susana Vaz<\/strong><\/a>, Clare Barnett<\/strong><\/a>, Tangentia Ventures<\/strong><\/a>, Vijay Thomas<\/strong><\/a>, Scotia Wealth Management<\/strong><\/a>, Manny Gill<\/strong><\/a>, Gautam Mohorikar<\/strong><\/a>, Vijay Parmar, CPA, CA<\/strong><\/a>, Frank Pantazopoulos, MBA, CFA<\/strong><\/a>, Ownr<\/strong><\/a>, Marco Morelli, MBA<\/strong><\/a>, BDO<\/strong><\/a>, Alim Bhayani, CPA, CA<\/strong><\/a>, Kiwi Charge<\/strong><\/a>, Abdel Ali, MBA, CFA<\/strong><\/a><\/p>\n

Remerciements particuliers \u00e0 TechTO, \u00e0 Megha Kandoi, \u00e0 Wil Costigan et \u00e0 toute l\u2019\u00e9quipe pour leur soutien et leur contribution \u00e0 la croissance de cet \u00e9cosyst\u00e8me.
\nUpasana Sharma<\/strong><\/a>, Mahendra Naik, Vijay Thomas, Kanchan Kumar, Jey Narayanan, Sokkappan, Zahin Hussain, Justin Lo, Vinay Dora K, Vijay Menon, Sai Charantimath, Manaswi Tiple, Nisarg Lakhmani<\/strong><\/a><\/p>\n

hashtag#TiEQuest2026<\/strong><\/a> hashtag#TiEToronto<\/strong><\/a> hashtag#Winners<\/strong><\/a> hashtag#Founders<\/strong><\/a> hashtag#ReshapingtheWorld<\/strong><\/a><\/p>\n

\u00c0 PROPOS DE NEXPLASMAGEN<\/p>\n

NexPlasmaGen fait converger le domaine \u00e9mergent de la biotechnologie du plasma froid vers un traitement personnalis\u00e9 du cancer. Nous d\u00e9veloppons des syst\u00e8mes \u00e0 plasma froid de haute pr\u00e9cision qui d\u00e9truit les cellules canc\u00e9reuses tout en \u00e9pargnant les tissus sains environnant la r\u00e9gion trait\u00e9e. La premi\u00e8re application de NexPlasmaGen concerne le traitement du cancer du sein suivi du cancer de la peau et des poumons. Son dispositif m\u00e9dical de plasma froid brevet\u00e9 a le potentiel de r\u00e9duire le taux de r\u00e9currence du cancer et les effets secondaires et la toxicit\u00e9 des th\u00e9rapies standards afin d\u2019en faire b\u00e9n\u00e9ficier les patientes.<\/p>\n

Contact<\/p>\n

Dr. Val\u00e9rie L\u00e9veill\u00e9, ing. M.Sc.A., PDG\/fondatrice<\/p>\n

Tel. 1-514-229-9458<\/p>\n

Courriel\u00a0: valerie.leveille@nexplasmagen.com<\/a><\/p>\n

Site web: https:\/\/nexplasmagen.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Montr\u00e9al \/ 28 mai 2026 \u2013NexPlasmaGen vient de remporter la comp\u00e9tition de la cat\u00e9gorie MedTech du \ud835\udde7\ud835\uddf6\ud835\uddd8\ud835\udde4\ud835\ude02\ud835\uddf2\ud835\ude00\ud835\ude01 \ud835\udfee\ud835\udfec\ud835\udfee\ud835\udff2, avec une bourse de 15 000 CAD\u00a0!   \ud83c\udf1f \ud835\uddda\ud835\uddee\ud835\uddf4\ud835\uddfb\ud835\uddee\ud835\uddfb\ud835\ude01\ud835\uddf2 \ud835\uddf1\ud835\uddf2 \ud835\uddf9\ud835\uddee \ud835\uddf0\ud835\uddee\ud835\ude01\ud835\uddf2\u0301\ud835\uddf4\ud835\uddfc\ud835\uddff\ud835\uddf6\ud835\uddf2 \ud835\udde0\ud835\uddf2\ud835\uddf1\ud835\udde7\ud835\uddf2\ud835\uddf0\ud835\uddf5Dr. Val\u00e9rie L\u00e9veill\u00e9 \u2014 fondatrice et PDG de NexPlasmaGen Leveille NexPlasmaGen fait progresser l\u2019innovation…<\/p>\n","protected":false},"author":2,"featured_media":17359,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"wds_primary_category":0,"footnotes":""},"categories":[56],"tags":[],"class_list":["post-17364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee"],"_links":{"self":[{"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/posts\/17364"}],"collection":[{"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/comments?post=17364"}],"version-history":[{"count":2,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/posts\/17364\/revisions"}],"predecessor-version":[{"id":17366,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/posts\/17364\/revisions\/17366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/media\/17359"}],"wp:attachment":[{"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/media?parent=17364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/categories?post=17364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nexplasmagen.com\/fr\/wp-json\/wp\/v2\/tags?post=17364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}